US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

22.81

-0.2900-1.26%

Post-market: 22.810.00000.00%19:30 EDT

Volume:471.46K

Turnover:10.76M

Market Cap:1.51B

PE:-7.34

High:24.23

Open:23.29

Low:22.40

Close:23.10

52wk High:30.99

52wk Low:10.30

Shares:66.17M

Float Shares:36.76M

Volume Ratio:0.96

T/O Rate:1.28%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1097

EPS(LYR):-2.5230

ROE:-41.01%

ROA:-26.14%

PB:3.22

PE(LYR):-9.04

Loading ...

Overview Company News Filings

Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Spyre Therapeutics (SYRE) and Henry Schein (HSIC)

Stock Track | Bicara Therapeutics Soars 5.68% Intraday on Phase 3 Trial Initiation and Financial Results

Bicara publishes corporate presentation on ficerafusp alfa in HPV-negative head and neck cancer

BRIEF-Bicara Therapeutics Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Business Update

Bicara Therapeutics reports Q4 EPS (68c), consensus (65c)

Earnings Flash (BCAX) Bicara Therapeutics Posts Q4 Net Loss $0.68 a Share, vs. FactSet Est of $0.67 Loss

MT Newswires Live

Bicara FY25 net loss widens to $138 million; Q4 net loss rises 78% to $37 million

Bicara Therapeutics Q4 EPS $(0.68), Inline

Benzinga Earnings

Stock Track | Bicara Therapeutics Soars 5.55% in Pre-market on Earnings Report Release

Bicara Therapeutics Inc - Q4 Net Loss $37.4 Mln; FY2025 Net Loss $138.0 Mln

THOMSON REUTERS

Bicara Therapeutics: Initiated Phase 3 of the Fortifi-Hn01 Pivotal Trial; Interim Analysis Expected Mid-2027

THOMSON REUTERS

Press Release: Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Calendar of U.S. Earnings Expected in the Week Ahead

Top News Today/Canada: Government Records C$5.07 Billion Budget Deficit

Bicara Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview

Calendar of U.S. Earnings Expected in the Week Ahead

Bicara Therapeutics; Chief Medical Officer David Raben disposes of 5,500 common shares worth $104,229

BofA Initiates Bicara Therapeutics at Buy With $35 Price Target

MT Newswires Live

Bicara Therapeutics Initiated at Buy by B of A Securities

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/BCAX/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":22.81,"timestamp":1789156800000,"preClose":23.1,"halted":0,"volume":471459,"hourTrading":{"tag":"盘后","latestPrice":22.81,"preClose":22.81,"latestTime":"19:30 EDT","volume":32918,"amount":750859.58,"timestamp":1789169406453,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01255411255411267,"floatShares":36762300,"shares":66172934,"eps":-3.109661,"marketStatus":"Market Closed","change":-0.29,"latestTime":"09-11 16:00:00 EDT","open":23.29,"high":24.23,"low":22.4,"amount":10755471.486276,"amplitude":0.079221,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.109661,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":23.1,"preHourTrading":{"tag":"盘前","latestPrice":23.5,"preClose":23.1,"latestTime":"09:23 EDT","volume":1,"amount":23.5,"timestamp":1789133006952,"change":0.4,"changeRate":0.017316,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":22.81,"preClose":22.81,"latestTime":"19:30 EDT","volume":32918,"amount":750859.58,"timestamp":1789169406453,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9576419364351475,"impliedVol":0.4697,"impliedVolPercentile":0.6574},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":36762300,"roa":"-26.14%","roe":"-41.01%","lyrEps":-2.523003,"volumeRatio":0.9576419364351475,"shares":66172934,"dividePrice":0,"high":24.23,"amplitude":0.079221,"preClose":23.1,"low":22.4,"week52Low":10.295,"pbRate":"3.22","week52High":30.99,"institutionHeld":0,"latestPrice":22.81,"eps":-3.109661,"divideRate":0,"volume":471459,"delay":0,"ttmEps":-3.109661,"open":23.29,"prevYearClose":16.83,"prevWeekClose":23.17,"prevMonthClose":23.12,"prevQuarterClose":29.69,"fiveDayClose":23.34,"twentyDayClose":23.63,"sixtyDayClose":21.95},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"BCAX","fiscalQuarterEnding":"2026/06","expectedEps":-0.77,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.82},{"market":"US","date":"2026-05-11","symbol":"BCAX","fiscalQuarterEnding":"2026/03","expectedEps":-0.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"pre","actualEps":-0.93},{"market":"US","date":"2026-03-30","symbol":"BCAX","fiscalQuarterEnding":"2025/12","expectedEps":-0.72,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5333,"hold":0.1333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5333,"analysts":15,"updateTime":1787112000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-09-11","current":-7.335205,"percent":0.680723,"low":-22.704836,"twenty":-12.207874,"median":-9.430022,"eighty":-6.958786,"high":-5.144536,"avg":-10.45355,"sd":4.085542,"marketCap":1528594775},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669},{"date":"2026-02-27","current":-8.759817,"twenty":-15.498177,"median":-8.759817,"eighty":-6.531952,"marketCap":1064501760},{"date":"2026-03-06","current":-9.890416,"twenty":-15.312456,"median":-8.853601,"eighty":-6.556096,"marketCap":1201893200},{"date":"2026-03-13","current":-10.269994,"twenty":-15.203584,"median":-8.927397,"eighty":-6.566815,"marketCap":1248019912},{"date":"2026-03-20","current":-10.045455,"twenty":-15.15052,"median":-9.021228,"eighty":-6.577062,"marketCap":1220733688},{"date":"2026-03-27","current":-10.114955,"twenty":-14.98767,"median":-9.07442,"eighty":-6.589163,"marketCap":1229179424},{"date":"2026-04-02","current":-9.728723,"twenty":-14.625375,"median":-9.090377,"eighty":-6.609609,"marketCap":1342077333},{"date":"2026-04-10","current":-10.431089,"twenty":-14.409462,"median":-9.148523,"eighty":-6.631964,"marketCap":1438968770},{"date":"2026-04-17","current":-11.356504,"twenty":-14.321633,"median":-9.207398,"eighty":-6.63974,"marketCap":1566629784},{"date":"2026-04-24","current":-10.839221,"twenty":-14.136826,"median":-9.386913,"eighty":-6.653842,"marketCap":1495270551},{"date":"2026-05-01","current":-10.241261,"twenty":-13.992274,"median":-9.457397,"eighty":-6.668268,"marketCap":1412781895},{"date":"2026-05-08","current":-10.980156,"twenty":-13.748914,"median":-9.551117,"eighty":-6.6946,"marketCap":1514712543},{"date":"2026-05-15","current":-8.624637,"twenty":-13.404917,"median":-9.536519,"eighty":-6.716778,"marketCap":1356784832},{"date":"2026-05-22","current":-8.703992,"twenty":-13.199982,"median":-9.448315,"eighty":-6.737692,"marketCap":1369268567},{"date":"2026-05-29","current":-9.084061,"twenty":-13.028804,"median":-9.388604,"eighty":-6.752117,"marketCap":1429059085},{"date":"2026-06-05","current":-8.524399,"twenty":-12.837909,"median":-9.249533,"eighty":-6.75968,"marketCap":1341015905},{"date":"2026-06-12","current":-8.887762,"twenty":-12.760238,"median":-9.180782,"eighty":-6.769997,"marketCap":1398178268},{"date":"2026-06-18","current":-9.572721,"twenty":-12.640072,"median":-9.17593,"eighty":-6.781418,"marketCap":1505932608},{"date":"2026-06-26","current":-11.001111,"twenty":-12.607001,"median":-9.207398,"eighty":-6.784967,"marketCap":1730639830},{"date":"2026-07-02","current":-12.074492,"twenty":-12.533268,"median":-9.343805,"eighty":-6.786535,"marketCap":1899498766},{"date":"2026-07-10","current":-12.396089,"twenty":-12.533268,"median":-9.434628,"eighty":-6.792442,"marketCap":1950090742},{"date":"2026-07-17","current":-11.52736,"twenty":-12.506498,"median":-9.486153,"eighty":-6.807115,"marketCap":1813426701},{"date":"2026-07-24","current":-11.581656,"twenty":-12.437044,"median":-9.561678,"eighty":-6.833787,"marketCap":1821968204},{"date":"2026-07-31","current":-10.971875,"twenty":-12.407622,"median":-9.577189,"eighty":-6.841301,"marketCap":1726040559},{"date":"2026-08-07","current":-11.489771,"twenty":-12.396924,"median":-9.702195,"eighty":-6.849841,"marketCap":1807513353},{"date":"2026-08-14","current":-8.435699,"twenty":-12.359992,"median":-9.679126,"eighty":-6.875132,"marketCap":1563666430},{"date":"2026-08-21","current":-8.707012,"twenty":-12.33633,"median":-9.572721,"eighty":-6.915667,"marketCap":1613957860},{"date":"2026-08-28","current":-8.864088,"twenty":-12.269802,"median":-9.54708,"eighty":-6.936947,"marketCap":1643073951},{"date":"2026-09-04","current":-8.332171,"twenty":-12.221805,"median":-9.457397,"eighty":-6.949118,"marketCap":1544476279},{"date":"2026-09-11","current":-8.246494,"twenty":-12.207874,"median":-9.430022,"eighty":-6.958786,"marketCap":1528594775}],"updateTime":1789209334019},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2623583958","title":"Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2623583958","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623583958?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:02","pubTimestamp":1774954920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 07:02 ET (11:02 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623588906","title":"Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Spyre Therapeutics (SYRE) and Henry Schein (HSIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623588906","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623588906?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:40","pubTimestamp":1774953609,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bicara Therapeutics Inc. (BCAX), Spyre Therapeutic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bicara-therapeutics-inc-bcax-spyre-therapeutics-syre-and-henry-schein-hsic-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bicara-therapeutics-inc-bcax-spyre-therapeutics-syre-and-henry-schein-hsic-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HSIC","LABU","BK4175","SYRE","BK4137","HCSG","LU0128526141.USD","BK4585","BK4588","BK4581","BCAX","XBI","LU0029874061.USD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139867125","title":"Stock Track | Bicara Therapeutics Soars 5.68% Intraday on Phase 3 Trial Initiation and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1139867125","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139867125?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:15","pubTimestamp":1774880121,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics' stock surged 5.68% during intraday trading on Monday, following the company's announcement of significant clinical progress and its fourth quarter and full year 2025 financial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623310536","title":"Bicara publishes corporate presentation on ficerafusp alfa in HPV-negative head and neck cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2623310536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623310536?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:31","pubTimestamp":1774873870,"startTime":"0","endTime":"0","summary":"Bicara outlined development strategy for lead asset ficerafusp alfa , an EGFR-directed antibody bound to a TGF-β ligand trap, targeting first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma.Phase 1b efficacy in HPV-negative, CPS≥1 first-line R/M HNSCC showed confirmed objective response rate 54% .Median duration of response was 21.7 months in HPV-negative patients receiving FICERA 1,500 mg weekly with pembrolizumab.Overall survival in same cohort showed median OS 21.3 months with 2-year OS rate 46%.Program timeline targets interim analysis in mid-2027 as Bicara expands signal-seeking studies into additional solid tumors, starting with metastatic colorectal cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL9MWVy4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623122803","title":"BRIEF-Bicara Therapeutics Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623122803","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623122803?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:59","pubTimestamp":1774871945,"startTime":"0","endTime":"0","summary":"BRIEF-Bicara Therapeutics Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Business UpdateMarch 30 (Reuters) - Bicara Therapeutics Inc BCAX.O:BICARA THERAPEUTICS REPORTS FOURTH","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9GLT2C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312822","title":"Bicara Therapeutics reports Q4 EPS (68c), consensus (65c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312822","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312822?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:41","pubTimestamp":1774870881,"startTime":"0","endTime":"0","summary":"As of December 31, 2025, Bicara had cash, cash equivalents and marketable securities of $414.8M, compared to $489.7M in cash and cash equivalents a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-reports-q4-eps-68c-consensus-65c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-reports-q4-eps-68c-consensus-65c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623147863","title":"Earnings Flash (BCAX) Bicara Therapeutics Posts Q4 Net Loss $0.68 a Share, vs. FactSet Est of $0.67 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2623147863","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623147863?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:38","pubTimestamp":1774870687,"startTime":"0","endTime":"0","summary":"Earnings Flash (BCAX) Bicara Therapeutics Posts Q4 Net Loss $0.68 a Share, vs. FactSet Est of $0.67 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314210","title":"Bicara FY25 net loss widens to $138 million; Q4 net loss rises 78% to $37 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314210","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314210?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:34","pubTimestamp":1774870442,"startTime":"0","endTime":"0","summary":"Bicara posted a Q4 net loss of USD 37 million, more than doubled from a year earlier.Full-year net loss widened to USD 140 million, while R&D spending climbed to USD 130 million due to costs tied to the FORTIFI-HN01 pivotal trial, Phase 1/1b expansion cohorts, and higher personnel expense.Cash, cash equivalents, and marketable securities totaled USD 410 million at year-end; an oversubscribed offering added USD 160 million in net proceeds in Q1.Phase 3 of the FORTIFI-HN01 study started with 1,500 mg weekly ficerafusp alfa selected as the optimal dose; interim analysis expected mid-2027.Company expects existing cash, cash equivalents, and marketable securities to fund operations into the first half of 2029.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL2lJjgN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4112","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4139","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","SG9999014039.USD","LU0314104364.USD","BCAX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623231443","title":"Bicara Therapeutics Q4 EPS $(0.68), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2623231443","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623231443?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:33","pubTimestamp":1774870397,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 74.36 percent decrease over losses of $(0.39) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51535064/bicara-therapeutics-q4-eps-0-68-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183833054","title":"Stock Track | Bicara Therapeutics Soars 5.55% in Pre-market on Earnings Report Release","url":"https://stock-news.laohu8.com/highlight/detail?id=1183833054","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183833054?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:32","pubTimestamp":1774870367,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics' stock surged 5.55% during pre-market trading on Monday, following the release of its fourth quarter and full year 2025 financial results and business update.The company was...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623731448","title":"Bicara Therapeutics Inc - Q4 Net Loss $37.4 Mln; FY2025 Net Loss $138.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623731448","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623731448?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9GLT2C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623415314","title":"Bicara Therapeutics: Initiated Phase 3 of the Fortifi-Hn01 Pivotal Trial; Interim Analysis Expected Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2623415314","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623415314?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9GLT2C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314495","title":"Press Release: Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314495","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314495?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870200,"startTime":"0","endTime":"0","summary":"Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027. Announced development of a less frequent loading and every-three-week maintenance dose of ficerafusp alfa. Corporate call to discuss financial results and business updates on Monday, March 30, 2026 at 8:30 a.m. ET. BOSTON, March 30, 2026  -- Bicara Therapeutics Inc.  today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update.\"Bicara enters the year with exceptional momentum across our clinical, regulatory, and corporate priorities,\" said Claire Mazumdar, Ph.D., Chief Executive Officer at Bicara Therapeutics. \"The continued advancement of our pivotal FORTIFI-HN01 study, the robust body of clinical data supporting ficerafusp alfa's differentiated profile, and the alternate dosing option for ficerafusp alfa all underscore the significant progress we've made toward transf","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0509642566.USD","BK4509","LU0359201612.USD","IE00BYQNZ168.SGD","BK4563","BK4531","BK4108","SG9999011746.SGD","BK4552","01698","BCAX","BK4565","LU0456842615.SGD","LU2039709279.SGD","IE00BYTNYN87.SGD","BK4526","BK4548","LU0269904917.USD","LU0828238088.HKD","IE00B12V2V27.USD","LU1023057109.AUD","BK4571","BK4139","LU0359202008.SGD","BK4535"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2623315199","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315199?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:00","pubTimestamp":1774864800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.26)  4:05 PM. ·Dave & Buster                                   4Q       .39   4:05 PM. ·NIKE Class B                                     3Q       .29   4:15 PM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INV","DMAC","SGMO","AIRJ","APOG","RNXT","BCAX","BYND","PROP","IMNN","PENG","PLAY","AIRO","NKLR","BTBT","PVLA","PRGS","LW","AYI","NGEN","BNZI","MKC","FC","NEOG","AEHR","PVH","RH","BIRD","CRDL","INMB","BEEM","KEEL","PHR","MAZE","NNOX","CAG","MKC.V","NCNO","FDS","BITF","LNN","AURA","BHST","NMRA","MSM","CALM","JILL","NKE","SGML","PRPL","ANGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622980815","title":"Top News Today/Canada: Government Records C$5.07 Billion Budget Deficit","url":"https://stock-news.laohu8.com/highlight/detail?id=2622980815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622980815?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:30","pubTimestamp":1774643400,"startTime":"0","endTime":"0","summary":"Canada recorded a deficit in January similar to the year-ago period, as both tax revenue and government spending declined in the month.Canada had a budget deficit of C$5.07 billion in January, the Department of Finance said Friday in its monthly Fiscal Monitor publication. This is largely in line with the C$5.13 billion deficit posted in January of last year. With just two months left in the 2025-26 fiscal year, Canada's budget deficit sits at C$31.21 billion, an increase of about 16% from the comparable year-ago period.The Liberal government's annual budget plan, issued in November, projected a C$78.3 billion deficit in the current fiscal year. Historically, finance ministry data tends to show sizable deficits in the month of March, or the last month of the fiscal year, due to adjustments to tax receipts.Statistics Canada Estimates Wholesale Trade Rose 2.3% in February. The estimate incorporates wholesale transactions excluding petroleum products, oilseeds and grains. The data agency ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INLX","FTHM","BK4147","CVV","HQI","BK4097","BK4130","BCLI","CYCN","IEF","BCAX","BK4161","BK4588","BK4120","AQMS","BK4079","CFA.SI","GNE","BK4081","BK4139","GALT","ANNX","BK4585","AIRJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873091","title":"Bicara Therapeutics Inc  expected to post a loss of 67 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873091","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622873091?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:14","pubTimestamp":1774624485,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc  expected to post a loss of67cents a share - Earnings Preview Bicara Therapeutics Inc BCAX.OQ BCAX.O is expected to  show no change in quarterly revenue when it reports  result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F1GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847966","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847966?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:00","pubTimestamp":1774605600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·SBC Med Grp Hld                                  4Q       .12       BMO. ·INmune Bio Inc                                  4Q      (.26)  4:05 PM. ·Banzai Intl Cl A                                4Q      (.59)      AMC. ·FactSet Res Sys                                  2Q      4.38   6:00 AM. ·McCormick & Co                                 1Q       .60   6:30 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEHR","FDS","ATOS","INMB","BCAX","PENG","MKC","APOG","PLAY","BTBT","KYTX","FC","HUMA","BYND","PHR","NKE","ANGO","NCNO","AIRO","CCL","MSLE","DEFT","BHST","NGEN","PRGS","LGN","NMRA","INV","JILL","BNZI","CAG","LW","BIRD","BEEM","BITF","AURA","RNXT","MKC.V","CRDL","MSM","DMAC","LNN","NEOG","AIRJ","KEEL","KOPN","AUTL","AYI","CALM","IMNN","NKLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622975808","title":"Bicara Therapeutics; Chief Medical Officer David Raben disposes of 5,500 common shares worth $104,229","url":"https://stock-news.laohu8.com/highlight/detail?id=2622975808","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622975808?lang=en_us&edition=fundamental","pubTime":"2026-03-27 07:21","pubTimestamp":1774567316,"startTime":"0","endTime":"0","summary":"David Raben, Chief Medical Officer at Bicara Therapeutics, reported transactions in the company’s common stock on 03/25/2026.He exercised stock options for 5,500 shares at USD 3.79 per share.He sold 5,500 shares at a weighted average price of USD 18.95 per share.Following the transactions, he reported direct ownership of 55,286 common shares.He also reported 47,413 stock options outstanding after the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for the informat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL5h0RQp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics; Chief Medical Officer David Raben disposes of 5,500 common shares worth $104,229","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622506074","title":"BofA Initiates Bicara Therapeutics at Buy With $35 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2622506074","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622506074?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:04","pubTimestamp":1774447461,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) has an average rating of buy and mean price target of $29.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622760600","title":"Bicara Therapeutics Initiated at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2622760600","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622760600?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:58","pubTimestamp":1774443480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 08:58 ET (12:58 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":130,"code":"91000000","status":"200"}]}}